Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer




Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer.

Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over $80 billion in annual revenue. In the UK, Tesco is the clear market leader, holding nearly 30% market share and serving millions of customers weekly through its extensive nationwide store network and robust online platform.

Expanding distribution through this established and trusted retail platform represents a meaningful advancement in Cosmos Health’s UK growth strategy and significantly enhances C-Scrub’s visibility, accessibility, and market credibility.

C-Scrub Listed on Tesco.com

C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Cosmos Health expects continued momentum for C-Scrub in the UK as it further strengthens retail partnerships and expands its distribution footprint.

Greg Siokas, CEO of Cosmos Health, stated: “C-Scrub’s entry into Tesco represents a pivotal moment for Cosmos. Building on our established online presence with Amazon, securing placement with the UK’s largest retailer significantly enhances our retail presence and strengthens our credibility in the market. Beyond the immediate growth opportunity for C-Scrub, this milestone establishes a powerful platform for the potential rollout of additional products from our portfolio over time, further solidifying our position in the UK and across broader European markets.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f55c572-5957-454e-81d1-fb1cb2a0ee0d

Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer




Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer.

Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over $80 billion in annual revenue. In the UK, Tesco is the clear market leader, holding nearly 30% market share and serving millions of customers weekly through its extensive nationwide store network and robust online platform.

Expanding distribution through this established and trusted retail platform represents a meaningful advancement in Cosmos Health’s UK growth strategy and significantly enhances C-Scrub’s visibility, accessibility, and market credibility.

C-Scrub Listed on Tesco.com

C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Cosmos Health expects continued momentum for C-Scrub in the UK as it further strengthens retail partnerships and expands its distribution footprint.

Greg Siokas, CEO of Cosmos Health, stated: “C-Scrub’s entry into Tesco represents a pivotal moment for Cosmos. Building on our established online presence with Amazon, securing placement with the UK’s largest retailer significantly enhances our retail presence and strengthens our credibility in the market. Beyond the immediate growth opportunity for C-Scrub, this milestone establishes a powerful platform for the potential rollout of additional products from our portfolio over time, further solidifying our position in the UK and across broader European markets.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f55c572-5957-454e-81d1-fb1cb2a0ee0d

Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease




Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease

Enterololin, a narrow-spectrum antibiotic uses a novel mechanism of action to attack the infection

HAMILTON, Ontario, Feb. 18, 2026 (GLOBE NEWSWIRE) — Stoked Bio Inc., a Canadian biotechnology company focused on the development of novel anti-infectives and cancer therapeutics, announced today it has secured an exclusive, global license from McMaster University for the patents covering Enterololin. Stoked Bio will lead the development of Enterololin, a promising narrow-spectrum antibiotic, as a potential therapeutic for conditions including Crohn’s disease.

Enterololin was discovered in the lab of Dr. Jon Stokes at McMaster and was the subject of a recent publication in Nature Microbiology describing the compound. The mechanism-of-action was rapidly predicted using AI tools in collaboration with researchers at the Massachusetts Institute of Technology, shortening what would normally be a lengthy experimental bottleneck and de-risking early development decisions. The licensed IP package and data set provide Stoked Bio with the exclusive rights to develop and the scientific foundation to optimize Enterololin for human use.

“This license agreement is a pivotal step in our mission to find new therapeutics for critical diseases,” said Jeff Skinner, CEO of Stoked Bio. “Enterololin was identified through a biology-first process and kills bacteria in a new way, setting it up to be an important future therapeutic option. We are committed to advancing this compound through development to improve the lives of patients.”

Enterololin selectively targets adherent-invasive E. coli, a pathogenic bacterium implicated in Crohn’s disease, with the potential to avoid the broad microbiome disruption characteristic of many existing antibiotics. The microbiome, all of the bacteria that live on and in us, is increasingly recognized as an important contributor to human health. By selectively targeting a key pathogen and avoiding collateral damage to gut microbes, Enterololin presents substantial opportunity to improve care for patients with Crohn’s disease.

“We’re excited to see Enterololin move into the hands of a company dedicated to turning academic discoveries into medicines,” added Dr. Jon Stokes. “This license ensures continuity between the lab and the clinic while preserving a close research collaboration between McMaster and Stoked Bio.”

About the agreement
Under the license, Stoked Bio has obtained global rights to the patents and related data covering Enterololin and will be responsible for further development, regulatory strategy and commercialization. McMaster retains a relationship with Stoked Bio that includes scientific collaboration and typical academic licensing terms intended to support both translational progress and academic stewardship of the discovery.

About the Stokes Lab, McMaster University
The Stokes lab (Department of Biochemistry & Biomedical Sciences) specializes in antibiotics and mechanisms of host–microbe interaction. The lab’s discovery of Enterololin and the AI-assisted mechanistic work were published in Nature Microbiology and covered in Canadian and international press. https://www.nature.com/articles/s41564-025-02142-0

About Stoked Bio
Stoked Bio is creating the path of least resistance by reengineering how therapies for drug-resistant diseases are discovered and developed. Our biology-first approach integrates proprietary, disease-specific training data with machine learning to identify compounds with real biological effect instead of just a statistical signal. By increasing the odds of success, we can accelerate timelines through early pharma partnerships to deliver strong near-term investor value. Our portfolio continues to expand with novel therapeutic options to treat important resistant diseases. For more information, visit https://stokedbio.com.

For more information:

Jeff Skinner, CEO
ir@stokedbio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/329b9213-22a1-486a-8b1c-2fe194309036

Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease




Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease

Enterololin, a narrow-spectrum antibiotic uses a novel mechanism of action to attack the infection

HAMILTON, Ontario, Feb. 18, 2026 (GLOBE NEWSWIRE) — Stoked Bio Inc., a Canadian biotechnology company focused on the development of novel anti-infectives and cancer therapeutics, announced today it has secured an exclusive, global license from McMaster University for the patents covering Enterololin. Stoked Bio will lead the development of Enterololin, a promising narrow-spectrum antibiotic, as a potential therapeutic for conditions including Crohn’s disease.

Enterololin was discovered in the lab of Dr. Jon Stokes at McMaster and was the subject of a recent publication in Nature Microbiology describing the compound. The mechanism-of-action was rapidly predicted using AI tools in collaboration with researchers at the Massachusetts Institute of Technology, shortening what would normally be a lengthy experimental bottleneck and de-risking early development decisions. The licensed IP package and data set provide Stoked Bio with the exclusive rights to develop and the scientific foundation to optimize Enterololin for human use.

“This license agreement is a pivotal step in our mission to find new therapeutics for critical diseases,” said Jeff Skinner, CEO of Stoked Bio. “Enterololin was identified through a biology-first process and kills bacteria in a new way, setting it up to be an important future therapeutic option. We are committed to advancing this compound through development to improve the lives of patients.”

Enterololin selectively targets adherent-invasive E. coli, a pathogenic bacterium implicated in Crohn’s disease, with the potential to avoid the broad microbiome disruption characteristic of many existing antibiotics. The microbiome, all of the bacteria that live on and in us, is increasingly recognized as an important contributor to human health. By selectively targeting a key pathogen and avoiding collateral damage to gut microbes, Enterololin presents substantial opportunity to improve care for patients with Crohn’s disease.

“We’re excited to see Enterololin move into the hands of a company dedicated to turning academic discoveries into medicines,” added Dr. Jon Stokes. “This license ensures continuity between the lab and the clinic while preserving a close research collaboration between McMaster and Stoked Bio.”

About the agreement
Under the license, Stoked Bio has obtained global rights to the patents and related data covering Enterololin and will be responsible for further development, regulatory strategy and commercialization. McMaster retains a relationship with Stoked Bio that includes scientific collaboration and typical academic licensing terms intended to support both translational progress and academic stewardship of the discovery.

About the Stokes Lab, McMaster University
The Stokes lab (Department of Biochemistry & Biomedical Sciences) specializes in antibiotics and mechanisms of host–microbe interaction. The lab’s discovery of Enterololin and the AI-assisted mechanistic work were published in Nature Microbiology and covered in Canadian and international press. https://www.nature.com/articles/s41564-025-02142-0

About Stoked Bio
Stoked Bio is creating the path of least resistance by reengineering how therapies for drug-resistant diseases are discovered and developed. Our biology-first approach integrates proprietary, disease-specific training data with machine learning to identify compounds with real biological effect instead of just a statistical signal. By increasing the odds of success, we can accelerate timelines through early pharma partnerships to deliver strong near-term investor value. Our portfolio continues to expand with novel therapeutic options to treat important resistant diseases. For more information, visit https://stokedbio.com.

For more information:

Jeff Skinner, CEO
ir@stokedbio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/329b9213-22a1-486a-8b1c-2fe194309036

Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform




Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform

Worcester, Massachusetts, Feb. 18, 2026 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST), a diversified innovation company with operations spanning eco-friendly products and collectibles monetization, today announced to increase awareness and drive exposure to the GoPaid platform and its collectibles ecosystem with an emphasis on the tokenization of collectibles will conduct a free sweepstakes for the next 14 days.

Following the release, we will coordinate a focused social media push on X. This campaign will involve posts designed to generate attention and conversation within the crypto and OTC investor communities. We will work with relevant X accounts in those spaces, to amplify reach and engagement.

• Sweepstakes: Winners will be chosen at random (by chance). We do not require a purchase or any form of “consideration” (payment, significant effort, or time) for entry. Buying something won’t help you win.
• To Be Eligible A person must go to the Vystar twitter account @VystarCompany follow the account, like the post, repost or comment and tag. Eligibility: Winners must be 18+, a U.S. resident, residing in the continental United States, all employees of Vystar, Capital R3alm & GOPAID.COM are excluded.
• Giveaway will include 10 prizes minimum 1 or more given daily, Monday through Friday starting on February 18, 2026.
• Prize Details: A full description of the prize and its Approximate Retail Value (ARV) will be posted daily. Prizes range from $25.00 – $250.00. Multiple prizes may be given daily.
• Winner Selection & Notification: Winner will be chosen randomly and will be contacted via “X” @JRC_Stocks.

GOPAID.COM, Capital R3alm and Vystar’s Partnership

Partnership Vision and Platform Development

Through the collaboration between Vystar, GoPaid, and Capital R3alm, the parties aim to redefine community finance by merging institutional-grade physical memorabilia with advanced Web3 infrastructure.

• GoPaid, led by the Rotman family, contributes more than a decade of experience in merchandise creation, VIP ticketing, and curated fan experiences for over 100 global music acts, supplying premium collectibles across music, sports, and non-sports categories.
• Vystar Corp. brings its diversified operating portfolio, including RxAir^™ air purification systems and Vytex^® natural rubber latex, along with public-company governance and capital markets experience.
• Capital R3alm, an Ohio-based C-Corporation operating as a regulated private investment company, provides a unified Web3 ecosystem for tokenization, trading, governance, analytics, and alerts.

Capital R3alm operates as a decentralized “digital kingdom,” integrating multiple subsidiaries and platforms to empower investors with ownership over their data, assets, and wealth in the Web3 era.

Platform Initiatives

The partnership will focus on three core initiatives:

Tokenization of Memorabilia

Iconic collectibles—such as Sports and Non-Sport Collectables, Music Memorabilia, Movie Posters and other collectables—are expected to be converted into fractional digital tokens, expanding global access and liquidity. Tokenization has the potential to unlock trillions in previously illiquid assets by transforming ownership and market access.

R3alm Collectibles Marketplace

A white-label marketplace targeted for launch in Q2 2026, integrating secure storage, asset protection, yield-bearing token structures, metaverse galleries, and DAO-based governance.

R3alm Oracle Network

A decentralized oracle network delivering real-time valuations, provenance verification, and market analytics for collectibles. The platform combines AI-driven analytics, zero-knowledge privacy frameworks, and cross-chain architecture, with governance supported by a dedicated utility token.

The initiative also extends to R3alm Music History Holdings (RMH), a vehicle designed to tokenize artist assets and integrate fan loyalty programs.

Market Opportunity and Financial Outlook

The global collectibles market—including fine art, sports memorabilia, NFTs, luxury items, and music merchandise—is projected to grow from approximately $464 billion in 2025 to over $900 billion by 2035. Management believes tokenization and blockchain verification will play an increasingly central role in liquidity, transparency, and global participation.

Internal projections for the combined initiatives indicate scalable revenue opportunities, expanding assets under management, and long-term valuation potential across collectibles, oracle services, and music-focused holdings.

Strategic Benefits for Vystar Shareholders

Vystar believes this transaction:

• Diversifies its portfolio into high-growth Web3 and real-world asset markets
• Creates multiple revenue participation paths through equity, token economics, and platform fees
• Enhances long-term shareholder value through early participation in tokenized collectibles infrastructure

The Company intends to provide ongoing updates as definitive agreements are finalized and milestones are achieved.

To Read Related Documents Please Click Here

About Vystar Corporation

Vystar Corporation (OTCQB: VYST) has four main areas of focus; Vytex, RXAIR, Fluid Energy Conversion (FEC), GOPAID.com. Vystar is confident it can succeed in spaces where it can make outstanding products that are protected by patents and copyrights. This precludes potential competitors from seeking to duplicate Vystar’s products.

GOPAID.com – products and strategic ventures in tokenization of collectibles and digital assets.

Vytex Allergy Free Natural Rubber Latex – The Company owns the formulations and intellectual property that creates what Vystar believes to be the highest quality products as against any competitor’s products. By way of example, Vystar can manufacture allergy and ammonia free natural latex products ranging from: (i) foam utilized in pillows, mattresses and toppers; (ii) gloves; (iii) condoms; and (iv) and other latex products. The Company believes its FDA approved products are unrivaled in the industry and maintains a substantial inventory warehoused in the United States. To view our products go to www.vytex.com.

RXAIR Residential and Medical Air Purification – Vystar has built a line of products for the home and medical facilities. The product lines range from a personal $500 unit to an industrial $6,000 unit for hospitals or similarly situated medical services. Vystar owns the patents and has achieved FDA approval, as well as EPA, CARB and other air purification certifications. Vystar has sold more than 20,000 residential and 400 hospital units RXAIR Video’s. In addition, Vystar has invested in manufacturing and high-speed tooling for the units. These units are built to eliminate germs, viruses and bacteria. Vystar maintains a stockpile of more than a thousand units and replacement cartridges. Also important, Vystar is under a medical device exemption from the recent tariffs. RXAIR AIR PURIFIER ONLINE STORE.

FEC – The Hughes Reactor changes flow of liquid or gas into sound waves. The sound can be brought to powerful levels using a mechanism that has no moving parts. This allows the reactor the ability to harness the energy into various uses. The uses for this patented technology include: Flow Meter, hard water abatement, air purification, multiple dialysis applications and combustion enhancements for natural gas, biofuels, gasoline. This energy is powerful, clean, and controllable. It can be used to measure flow, to push forward chemical reactions such as combustion, or to mix chemicals together thoroughly and instantly. All of this technology is protected by Vystar’s intellectual property.

Investor Relations & Media Contact
Vystar Corporation
https://vystarcorp.com/investor-relations
https://gopaid.com
https://r3alm.com/

Follow us on social media:

Twitter:@VystarCompany @RxAir
Facebook: @RxAir
Instagram:@rxair_air_purification

Forward-Looking Statements

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements. *X (Formerly Twitter) is in no way sponsoring or endorsing this sweepstakes/promotion.

Contacts:

Vystar
Media & Investors: Jamie Rotman, jrotman@vytex.com
Distributor Opportunities: info@rxair.com
Media, Investors or To Partner with Vystar, Company
Phone Number: (508) 791-9114
For information on FEC partnerships, contact info@Rxair.com or 508-791-9114

Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform




Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform

Worcester, Massachusetts, Feb. 18, 2026 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST), a diversified innovation company with operations spanning eco-friendly products and collectibles monetization, today announced to increase awareness and drive exposure to the GoPaid platform and its collectibles ecosystem with an emphasis on the tokenization of collectibles will conduct a free sweepstakes for the next 14 days.

Following the release, we will coordinate a focused social media push on X. This campaign will involve posts designed to generate attention and conversation within the crypto and OTC investor communities. We will work with relevant X accounts in those spaces, to amplify reach and engagement.

• Sweepstakes: Winners will be chosen at random (by chance). We do not require a purchase or any form of “consideration” (payment, significant effort, or time) for entry. Buying something won’t help you win.
• To Be Eligible A person must go to the Vystar twitter account @VystarCompany follow the account, like the post, repost or comment and tag. Eligibility: Winners must be 18+, a U.S. resident, residing in the continental United States, all employees of Vystar, Capital R3alm & GOPAID.COM are excluded.
• Giveaway will include 10 prizes minimum 1 or more given daily, Monday through Friday starting on February 18, 2026.
• Prize Details: A full description of the prize and its Approximate Retail Value (ARV) will be posted daily. Prizes range from $25.00 – $250.00. Multiple prizes may be given daily.
• Winner Selection & Notification: Winner will be chosen randomly and will be contacted via “X” @JRC_Stocks.

GOPAID.COM, Capital R3alm and Vystar’s Partnership

Partnership Vision and Platform Development

Through the collaboration between Vystar, GoPaid, and Capital R3alm, the parties aim to redefine community finance by merging institutional-grade physical memorabilia with advanced Web3 infrastructure.

• GoPaid, led by the Rotman family, contributes more than a decade of experience in merchandise creation, VIP ticketing, and curated fan experiences for over 100 global music acts, supplying premium collectibles across music, sports, and non-sports categories.
• Vystar Corp. brings its diversified operating portfolio, including RxAir^™ air purification systems and Vytex^® natural rubber latex, along with public-company governance and capital markets experience.
• Capital R3alm, an Ohio-based C-Corporation operating as a regulated private investment company, provides a unified Web3 ecosystem for tokenization, trading, governance, analytics, and alerts.

Capital R3alm operates as a decentralized “digital kingdom,” integrating multiple subsidiaries and platforms to empower investors with ownership over their data, assets, and wealth in the Web3 era.

Platform Initiatives

The partnership will focus on three core initiatives:

Tokenization of Memorabilia

Iconic collectibles—such as Sports and Non-Sport Collectables, Music Memorabilia, Movie Posters and other collectables—are expected to be converted into fractional digital tokens, expanding global access and liquidity. Tokenization has the potential to unlock trillions in previously illiquid assets by transforming ownership and market access.

R3alm Collectibles Marketplace

A white-label marketplace targeted for launch in Q2 2026, integrating secure storage, asset protection, yield-bearing token structures, metaverse galleries, and DAO-based governance.

R3alm Oracle Network

A decentralized oracle network delivering real-time valuations, provenance verification, and market analytics for collectibles. The platform combines AI-driven analytics, zero-knowledge privacy frameworks, and cross-chain architecture, with governance supported by a dedicated utility token.

The initiative also extends to R3alm Music History Holdings (RMH), a vehicle designed to tokenize artist assets and integrate fan loyalty programs.

Market Opportunity and Financial Outlook

The global collectibles market—including fine art, sports memorabilia, NFTs, luxury items, and music merchandise—is projected to grow from approximately $464 billion in 2025 to over $900 billion by 2035. Management believes tokenization and blockchain verification will play an increasingly central role in liquidity, transparency, and global participation.

Internal projections for the combined initiatives indicate scalable revenue opportunities, expanding assets under management, and long-term valuation potential across collectibles, oracle services, and music-focused holdings.

Strategic Benefits for Vystar Shareholders

Vystar believes this transaction:

• Diversifies its portfolio into high-growth Web3 and real-world asset markets
• Creates multiple revenue participation paths through equity, token economics, and platform fees
• Enhances long-term shareholder value through early participation in tokenized collectibles infrastructure

The Company intends to provide ongoing updates as definitive agreements are finalized and milestones are achieved.

To Read Related Documents Please Click Here

About Vystar Corporation

Vystar Corporation (OTCQB: VYST) has four main areas of focus; Vytex, RXAIR, Fluid Energy Conversion (FEC), GOPAID.com. Vystar is confident it can succeed in spaces where it can make outstanding products that are protected by patents and copyrights. This precludes potential competitors from seeking to duplicate Vystar’s products.

GOPAID.com – products and strategic ventures in tokenization of collectibles and digital assets.

Vytex Allergy Free Natural Rubber Latex – The Company owns the formulations and intellectual property that creates what Vystar believes to be the highest quality products as against any competitor’s products. By way of example, Vystar can manufacture allergy and ammonia free natural latex products ranging from: (i) foam utilized in pillows, mattresses and toppers; (ii) gloves; (iii) condoms; and (iv) and other latex products. The Company believes its FDA approved products are unrivaled in the industry and maintains a substantial inventory warehoused in the United States. To view our products go to www.vytex.com.

RXAIR Residential and Medical Air Purification – Vystar has built a line of products for the home and medical facilities. The product lines range from a personal $500 unit to an industrial $6,000 unit for hospitals or similarly situated medical services. Vystar owns the patents and has achieved FDA approval, as well as EPA, CARB and other air purification certifications. Vystar has sold more than 20,000 residential and 400 hospital units RXAIR Video’s. In addition, Vystar has invested in manufacturing and high-speed tooling for the units. These units are built to eliminate germs, viruses and bacteria. Vystar maintains a stockpile of more than a thousand units and replacement cartridges. Also important, Vystar is under a medical device exemption from the recent tariffs. RXAIR AIR PURIFIER ONLINE STORE.

FEC – The Hughes Reactor changes flow of liquid or gas into sound waves. The sound can be brought to powerful levels using a mechanism that has no moving parts. This allows the reactor the ability to harness the energy into various uses. The uses for this patented technology include: Flow Meter, hard water abatement, air purification, multiple dialysis applications and combustion enhancements for natural gas, biofuels, gasoline. This energy is powerful, clean, and controllable. It can be used to measure flow, to push forward chemical reactions such as combustion, or to mix chemicals together thoroughly and instantly. All of this technology is protected by Vystar’s intellectual property.

Investor Relations & Media Contact
Vystar Corporation
https://vystarcorp.com/investor-relations
https://gopaid.com
https://r3alm.com/

Follow us on social media:

Twitter:@VystarCompany @RxAir
Facebook: @RxAir
Instagram:@rxair_air_purification

Forward-Looking Statements

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements. *X (Formerly Twitter) is in no way sponsoring or endorsing this sweepstakes/promotion.

Contacts:

Vystar
Media & Investors: Jamie Rotman, jrotman@vytex.com
Distributor Opportunities: info@rxair.com
Media, Investors or To Partner with Vystar, Company
Phone Number: (508) 791-9114
For information on FEC partnerships, contact info@Rxair.com or 508-791-9114

Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)




Alembic Therapeutics LLC Announces the Launch of PIVYA® (pivmecillinam)

Pivya^® (pivmecillinam) Tablets, 185mg

Now Available by Prescription in the United States

BEDMINSTER, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) — Alembic Therapeutics is pleased to announce the U.S. availability of Pivya^® (pivmecillinam) tablets, 185mg, an oral prescription antibiotic. Pivya contains pivmecillinam, a beta-lactam antibacterial agent with a long history of use internationally. PIVYA^® is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA^® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

“We are pleased to announce the availability and launch of Pivya into the US market. The commercialization of PIVYA is an important step in Alembic’s strategic goal to provide branded pharmaceutical products to the U.S. healthcare market,” said Craig Salmon, CEO of Alembic Therapeutics, LLC. “PIVYA will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on specialty segments and is the first of several launches into Women’s Healthcare.”

“I am excited to have PIVYA now available in the US. Pivya has been routinely and successfully used for over 40 years in Europe and Canada with minimal change in the antibiotic resistance rate,” said Dr. Keith Kaye, Division Chief of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School. “With a novel mechanism of action, not previously deployed in the U.S., PIVYA can become a cornerstone of the treatment of urinary tract infections, as it has traditionally been positioned as a first-line option by in the Infectious Disease Society of America treatment guidelines.”

Pivya^® tablets are supplied as 185mg pivmecillinam tablets, film-coated in child-resistant aluminum-aluminum push through blisters. Available pack sizes: 9 tablets (1 blister sheet with 9 tablets) NDC 62332-966-09. Pivya^® is supplied and manufactured in accordance with U.S. regulatory and quality standards.

This product is now available in the United States and is intended for use as prescribed by a Healthcare professional. Healthcare providers should consult the full prescribing information for complete details regarding approved indications, dosing, administration, contraindications, warnings, and safety information.

Alembic Therapeutics is committed to providing high-quality prescription medicines to support patient care and healthcare delivery. The launch of Pivya reflects our ongoing focus on Quality, Reliability, and Access.

Alembic Therapeutics, LLC
550 Hills Drive, Suite 110
Bedminster NJ 07921
www.alembictherapeutics.com
Sales@alembictx.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69b35530-7d24-42ef-b4e9-615460e2ec2f 

NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production




NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production

Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line

LAUSANNE, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) — NewBiologix S.A., a biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, today announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026).

The paper (1), authored by NewBiologix, covers the generation and characterization of NBX1P01, the company’s proprietary clonal HEK293 cell line optimized for rAAV production. Derived from more than 2,000 single-cell clones, NBX1P01 was selected for enhanced production performance and validated through extensive genomic sequencing to confirm clonality and stability. This clonal cell line underpins rapid, effective, and scalable production of viral vectors central to gene therapy manufacturing.

After comprehensive evaluation, the publication reports the following key findings:

• Full-to-empty capsid ratio: In head-to-head studies using identical protocols, NBX1P01 demonstrated a two-fold higher full-to-empty rAAV capsid ratio compared to a leading commercial HEK293 cell line. Full capsid content is a critical product quality attribute in rAAV manufacturing.
• Genomic stability: The clone remained genomically stable over 55 population doubling levels and exhibited lower genetic heterogeneity than the parental HEK293 population.
• Genome integrity: Long-read sequencing confirmed more than 70% intact rAAV genomes with minimal encapsidated contaminating DNA.
• Scalability and versatility: NBX1P01 demonstrated consistent performance across production volumes ranging from 10 mL to 1.5 L and supported multiple rAAV serotypes and clinically relevant transgene sizes.

Igor Fisch, CEO and Co-founder of NewBiologix, said, “As the gene therapy landscape evolves, manufacturing platforms must radically improve in performance. Our goal is to help revolutionize gene therapy by ushering in a more reliable and consistent industrial scale manufacturing foundation. This peer-reviewed publication validates our precision-built, high performance, stable HEK293 platform and showcases its reliability and consistency for quality rAAV production.”

Efrain Guzman, VP, Innovation & Business Development at NewBiologix, said, “We’re determined to make gene therapies more accessible and provide safe and effective therapies to patients. In viral vector manufacturing, quality is essential to assure the product’s integrity from day one. Choosing a reliable, stable and adaptable cell line that demonstrates consistent performance is foundational to achieving that goal.”

Manufacturing scalability and product quality remain central challenges in rAAV-based gene therapy development, particularly as programs expand beyond rare diseases into broader patient populations. Improvements in cell line stability impact product quality and dramatically reduce variability, thereby increasing manufacturing efficiency and enhancing overall product consistency.

For additional technical information, see the company’s latest Scientific White Paper (2).

References

(1) Generation and characterization of a HEK293 cell line optimized for recombinant adeno-associated virus production: https://doi.org/10.1016/j.btre.2026.e00948

(2) Unlocking Scalable, High-Quality rAAV Production with Xcell™ Eng-HEK293: https://145175225.hs-sites-eu1.com/white-paper-hek293

About NewBiologix S.A.
NewBiologix is a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through its proprietary, high performance, stable HEK293 platform technology. Headquartered in Lausanne, Switzerland, and backed by a world-class scientific team and leading investors, the company focuses on addressing one of the most critical bottlenecks in gene therapy: reproducible, cost-efficient, and high-quality vector manufacturing. By integrating its proprietary HEK293-based cell lines with its suite of advanced production tools, NewBiologix supports partners from research through commercialization to enable more consistent and reliable gene therapy manufacturing.

Visit our website and follow us on LinkedIn.

Media contacts

NewBiologix
Igor Fisch, CEO
contact@newbiologix.com

Scius Communications (for NewBiologix)
Katja Stout, katja@sciuscommunications.com
+44 7789 435990

Daniel Gooch, daniel@sciuscommunications.com
+44 7747 875479

NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production




NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production

Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line

LAUSANNE, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) — NewBiologix S.A., a biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, today announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026).

The paper (1), authored by NewBiologix, covers the generation and characterization of NBX1P01, the company’s proprietary clonal HEK293 cell line optimized for rAAV production. Derived from more than 2,000 single-cell clones, NBX1P01 was selected for enhanced production performance and validated through extensive genomic sequencing to confirm clonality and stability. This clonal cell line underpins rapid, effective, and scalable production of viral vectors central to gene therapy manufacturing.

After comprehensive evaluation, the publication reports the following key findings:

• Full-to-empty capsid ratio: In head-to-head studies using identical protocols, NBX1P01 demonstrated a two-fold higher full-to-empty rAAV capsid ratio compared to a leading commercial HEK293 cell line. Full capsid content is a critical product quality attribute in rAAV manufacturing.
• Genomic stability: The clone remained genomically stable over 55 population doubling levels and exhibited lower genetic heterogeneity than the parental HEK293 population.
• Genome integrity: Long-read sequencing confirmed more than 70% intact rAAV genomes with minimal encapsidated contaminating DNA.
• Scalability and versatility: NBX1P01 demonstrated consistent performance across production volumes ranging from 10 mL to 1.5 L and supported multiple rAAV serotypes and clinically relevant transgene sizes.

Igor Fisch, CEO and Co-founder of NewBiologix, said, “As the gene therapy landscape evolves, manufacturing platforms must radically improve in performance. Our goal is to help revolutionize gene therapy by ushering in a more reliable and consistent industrial scale manufacturing foundation. This peer-reviewed publication validates our precision-built, high performance, stable HEK293 platform and showcases its reliability and consistency for quality rAAV production.”

Efrain Guzman, VP, Innovation & Business Development at NewBiologix, said, “We’re determined to make gene therapies more accessible and provide safe and effective therapies to patients. In viral vector manufacturing, quality is essential to assure the product’s integrity from day one. Choosing a reliable, stable and adaptable cell line that demonstrates consistent performance is foundational to achieving that goal.”

Manufacturing scalability and product quality remain central challenges in rAAV-based gene therapy development, particularly as programs expand beyond rare diseases into broader patient populations. Improvements in cell line stability impact product quality and dramatically reduce variability, thereby increasing manufacturing efficiency and enhancing overall product consistency.

For additional technical information, see the company’s latest Scientific White Paper (2).

References

(1) Generation and characterization of a HEK293 cell line optimized for recombinant adeno-associated virus production: https://doi.org/10.1016/j.btre.2026.e00948

(2) Unlocking Scalable, High-Quality rAAV Production with Xcell™ Eng-HEK293: https://145175225.hs-sites-eu1.com/white-paper-hek293

About NewBiologix S.A.
NewBiologix is a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through its proprietary, high performance, stable HEK293 platform technology. Headquartered in Lausanne, Switzerland, and backed by a world-class scientific team and leading investors, the company focuses on addressing one of the most critical bottlenecks in gene therapy: reproducible, cost-efficient, and high-quality vector manufacturing. By integrating its proprietary HEK293-based cell lines with its suite of advanced production tools, NewBiologix supports partners from research through commercialization to enable more consistent and reliable gene therapy manufacturing.

Visit our website and follow us on LinkedIn.

Media contacts

NewBiologix
Igor Fisch, CEO
contact@newbiologix.com

Scius Communications (for NewBiologix)
Katja Stout, katja@sciuscommunications.com
+44 7789 435990

Daniel Gooch, daniel@sciuscommunications.com
+44 7747 875479

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada




Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine, MVA-BN^®.

This order, awarded under the existing 10-year contract framework established with PHAC in 2022, will ensure manufacturing of bulk vaccine product in 2026, with filling and supply of the final drug product to occur later.

With this award, Bavarian Nordic has now secured orders in its Public Preparedness business in 2026 for approximately DKK 1,400 million, an increase of DKK 100 million compared to latest communication. The full-year guidance for this business in 2026 remains unchanged at DKK 1,800-2,000 million.

“Public preparedness has remained a high priority in Canada for years, and we are proud to continue to support the government’s commitment to protecting its citizens against serious health threats, like mpox and smallpox,” said Paul Chaplin, President & CEO of Bavarian Nordic. “It is our aim to build and strengthen collaborations like this, as we have also done for decades with the US government through BARDA, and more recently with the EU through HERA, to facilitate a stronger public health response as a critical part of the defense against viral threats globally.”

About the mpox/smallpox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS^®), Canada (marketed as IMVAMUNE^®), and the EU/EAA and United Kingdom (marketed as IMVANEX^®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Attachment

• Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada